日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

比美替尼和恩科拉非尼治疗携带非V600E BRAF突变的晚期实体瘤:来自II期BEAVER试验的结果

April A N Rose #,Jennifer Maxwell #,Emmanuelle Rousselle #,Chantel L Mukonoweshuro,Islam E Elkholi,Melody Riaud,Marco Biondini,Erica Cianfarano,Isabel Soria-Bretones,Chantal Tobin,Meghan McGuire,Rhoda W Y Law,Andrew J Elia,Ben X Wang,Ian King,Tong Zhang,Trevor J Pugh,Zaid Saeed Kamil,Marcus Butler,Frances A Shepherd,Natasha B Leighl,Albiruni Abdul Razak,Aaron Hansen,Samuel D Saibil,Philippe L Bedard,Peter M Siegel,Lillian L Siu,David W Cescon,Anna Spreafico

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors

Cergutuzumab Amunaleukin 与 Atezolizumab 联合治疗癌胚抗原阳性晚期/转移性实体瘤患者

Melero, Ignacio; Tabernero, Josep; Steeghs, Neeltje; Robbrecht, Debbie G J; Peters, Solange; Rizvi, Naiyer A; O'Reilly, Eileen M; Calvo, Emiliano; Eefsen, Rikke L; Leighl, Natasha; Cervantes, Andres; Hafez, Navid; Habigt, Christin; Andersson, Emilia; Dejardin, David; Rossmann, Eva; Martinez Quetglas, Iris; Babitzki, Galina; Duarte, José; Adessi, Celine; Boetsch, Christophe; Evers, Stefan; Charo, Jehad; Teichgräber, Volker; Lassen, Ulrik

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

RET 改变实体瘤中选择性 RET 抑制剂耐药的基因组机制图谱:RETregistry 全球联盟分析

Waliany, Sarah; Cooper, Alissa J; Liu, Stephen V; Gautschi, Oliver; Rotow, Julia K; Smith, Katherine Emilie Rhoades; Weber, Urs M; Lee, Dae Ho; Loong, Herbert H F; Patel, Jyoti D; Pennell, Nathan A; Nagasaka, Misako; Patel, Shetal A; Tan, Daniel S W; Solomon, Benjamin J; Kim, Tae Min; Pall, Georg; Riess, Jonathan W; Sun, Lova; Früh, Martin; Uy, Natalie F; Gadgeel, Shirish; Feng, Jamie; Do, Andrew; Falcon, Christina; Leighl, Natasha B; Baik, Christina S; Lai, Gillianne G Y; Ou, S Ignatius; Cheung, Kingsley S Y; Patil, Tejas; Mansfield, Aaron S; Weiler, Daniela; Yeap, Beow Y; Wirth, Lori J; Gainor, Justin F; Drilon, Alexander; Lin, Jessica J

Global advances and future directions in lung cancer care: expert consensus and strategic priorities

全球肺癌治疗进展及未来方向:专家共识和战略重点

Meyer, M-L; Peters, S; Jänne, P A; Mok, T S; Bunn, P A; Abdel Karim, N; Altorki, N K; Arrieta, O; Bar, J; Cappuzzo, F; Carbone, D; Dacic, S; Diehn, M; Dziadziuszko, R; Felip, E; Flores, R; Florez, N; Forde, P M; Gainor, J F; Gray, J E; Gros, L; Halmos, B; Henschke, C I; Herbst, R; Heymach, J V; Kelly, K; Kris, M G; Leighl, N B; Mathias, C; Marron, T U; Mulshine, J L; Naidoo, J; Osarogiagbon, R; Passaro, A; Peled, N; Planchard, D; Politi, K; Popat, S; Pyenson, B; Reckamp, K L; Ren, S H; Riely, G J; Rolfo, C; Rudin, C M; Sen, T; Shields, M D; Singh, H; Skoulidis, F; Solomon, B J; Stahel, R; Stiles, B M; Syrigos, K; Yang, J C-H; Yang, P-C; Wolf, A; Wozniak, A J; Waqar, S N; Wakelee, H; Hirsch, F R

Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC

ALK突变型非小细胞肺癌酪氨酸激酶抑制剂的重量、BSA、毒性和疗效

Munarriz, Beatriz Jimenez; Khan, Sameena; Hueniken, Katrina; Tam, Shirley; Patel, Devalben; Zhan, Luna; Brown, Catherine; Eng, Lawson; Sacher, Adrian; Bradbury, Penelope; Leighl, Natasha; Liu, Geoffrey; Shepherd, Frances A

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

作者更正:CTLA4阻断可消除KEAP1/STK11相关的PD-(L)1抑制剂耐药性

Skoulidis, Ferdinandos; Araujo, Haniel A; Do, Minh Truong; Qian, Yu; Sun, Xin; Cobo, Ana Galan; Le, John T; Montesion, Meagan; Palmer, Rachael; Jahchan, Nadine; Juan, Joseph M; Min, Chengyin; Yu, Yi; Pan, Xuewen; Arbour, Kathryn C; Vokes, Natalie; Schmidt, Stephanie T; Molkentine, David; Owen, Dwight H; Memmott, Regan; Patil, Pradnya D; Marmarelis, Melina E; Awad, Mark M; Murray, Joseph C; Hellyer, Jessica A; Gainor, Justin F; Dimou, Anastasios; Bestvina, Christine M; Shu, Catherine A; Riess, Jonathan W; Blakely, Collin M; Pecot, Chad V; Mezquita, Laura; Tabbó, Fabrizio; Scheffler, Matthias; Digumarthy, Subba; Mooradian, Meghan J; Sacher, Adrian G; Lau, Sally C M; Saltos, Andreas N; Rotow, Julia; Johnson, Rocio Perez; Liu, Corinne; Stewart, Tyler; Goldberg, Sarah B; Killam, Jonathan; Walther, Zenta; Schalper, Kurt; Davies, Kurtis D; Woodcock, Mark G; Anagnostou, Valsamo; Marrone, Kristen A; Forde, Patrick M; Ricciuti, Biagio; Venkatraman, Deepti; Van Allen, Eliezer M; Cummings, Amy L; Goldman, Jonathan W; Shaish, Hiram; Kier, Melanie; Katz, Sharyn; Aggarwal, Charu; Ni, Ying; Azok, Joseph T; Segal, Jeremy; Ritterhouse, Lauren; Neal, Joel W; Lacroix, Ludovic; Elamin, Yasir Y; Negrao, Marcelo V; Le, Xiuning; Lam, Vincent K; Lewis, Whitney E; Kemp, Haley N; Carter, Brett; Roth, Jack A; Swisher, Stephen; Lee, Richard; Zhou, Teng; Poteete, Alissa; Kong, Yifan; Takehara, Tomohiro; Paula, Alvaro Guimaraes; Parra Cuentas, Edwin R; Behrens, Carmen; Wistuba, Ignacio I; Zhang, Jianjun; Blumenschein, George R; Gay, Carl; Byers, Lauren A; Gibbons, Don L; Tsao, Anne; Lee, J Jack; Bivona, Trever G; Camidge, D Ross; Gray, Jhannelle E; Leighl, Natasha B; Levy, Benjamin; Brahmer, Julie R; Garassino, Marina C; Gandara, David R; Garon, Edward B; Rizvi, Naiyer A; Scagliotti, Giorgio Vittorio; Wolf, Jürgen; Planchard, David; Besse, Benjamin; Herbst, Roy S; Wakelee, Heather A; Pennell, Nathan A; Shaw, Alice T; Jänne, Pasi A; Carbone, David P; Hellmann, Matthew D; Rudin, Charles M; Albacker, Lee; Mann, Helen; Zhu, Zhou; Lai, Zhongwu; Stewart, Ross; Peters, Solange; Johnson, Melissa L; Wong, Kwok K; Huang, Alan; Winslow, Monte M; Rosen, Michael J; Winters, Ian P; Papadimitrakopoulou, Vassiliki A; Cascone, Tina; Jewsbury, Philip; Heymach, John V

Mitigation and management of adverse events associated with amivantamab therapy

缓解和管理与阿米伐他单抗治疗相关的不良事件

Florez, Narjust; LeBoeuf, Nicole R; Rotow, Julia; Marks, Jennifer A; Sabari, Joshua K; Arrieta, Oscar; Baldotto, Clarissa; Gosain, Rahul; Zawisza, Dianne; McDonald, Stephanie; Dylgjeri, Emanuela; Cifuentes, Paul; McLellan, Beth; Leighl, Natasha B

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer

癌基因驱动的晚期非小细胞肺癌新型疗法的不断发展

Melosky, Barbara; Juergens, Rosalyn A; Banerji, Shantanu; Sacher, Adrian; Wheatley-Price, Paul; Snow, Stephanie; Tsao, Ming-Sound; Leighl, Natasha B; Martins, Ilidio; Cheema, Parneet; Liu, Geoffrey; Chu, Quincy S C

Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions

晚期KRAS G12C突变型非小细胞肺癌的免疫治疗:当前策略和未来方向

Ghazali, Nadia; Garassino, Marina C; Leighl, Natasha B; Bestvina, Christine M

Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)

非小细胞肺癌驱动致癌基因改变的频率及欧洲室内氡暴露量估计(欧洲氡研究)

García-Pardo, Miguel; García de Herreros, Marta; Auclin, Edouard; Ferriol-Galmes, Miquel; Laguna, Juan Carlos; Gorría, Teresa; Caravaca, Gerard; Sart, Joan; Albarrán-Artahona, Víctor; López-Castro, Rafael; Teixidó, Cristina; Castellano, Giancarlo; Martínez Bedmar, Alex; Arcocha, Ainara; Alcolea, Laura; Jiménez, Manuel; Bernabeu, Mario; Delgado-Cano, David; Navarro, Alejandro; Prat, Aleix; Reguart, Noemí; Elio, Javier; Garrido, Pilar; Leighl, Natasha B; Besse, Benjamin; Mezquita, Laura